| Symbol | ILMN |
|---|---|
| Name | ILLUMINA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 5200 ILLUMINA WAY, SAN DIEGO, California, 92122, United States |
| Telephone | +1 858 202-4500 |
| Fax | — |
| — | |
| Website | https://www.illumina.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001110803 |
| Description | Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illuminas high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Additional info from NASDAQ: |
2026-08-12 17:22
New Form 424B2 - ILLUMINA, INC. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001193125-26-346923 <b>Size:</b> 652 KB
Read more
2026-08-12 12:00
(99% Neutral) ILLUMINA, INC. (ILMN) Announces Update on Collaboration with Registrant
Read more
2026-08-11 17:22
New Form 3 - ILLUMINA, INC. <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0001110803-26-000171 <b>Size:</b> 5 KB
Read more
2026-08-10 17:59
New Form FWP - ILLUMINA, INC. <b>Filed:</b> 2026-08-10 <b>AccNo:</b> 0001193125-26-342610 <b>Size:</b> 18 KB
Read more
2026-08-10 09:13
New Form 424B2 - ILLUMINA, INC. <b>Filed:</b> 2026-08-10 <b>AccNo:</b> 0001193125-26-341332 <b>Size:</b> 506 KB
Read more
2026-08-07 20:56
Sullivan Michael C 🟢 acquired 15.0K shares (2 derivative) of ILLUMINA, INC. (ILMN) at $199.87 Transaction Date: Aug 05, 2026 | Filing ID: 000169
Read more
2026-08-03 20:24
Davies Scott M 🔴 sold 615 shares of ILLUMINA, INC. (ILMN) at $200.00 Transaction Date: Jul 30, 2026 | Filing ID: 000161
Read more
2026-07-30 20:22
📋 SCOTT DAVIES (Officer) plans to sell 615 shares of ILLUMINA INC (at $194.82 each, total $120K) Filed: Jul 30, 2026 | ID: 007435
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07176286 | 18F-mFBG Cardiac Uptake With Lewy Body Dementia | Phase2 | Parkinson Disease (PD) | Recruiting | 2026-04-30 | 2026-12-30 | ClinicalTrials.gov |
| NCT06965621 | 18F-mFBG Imaging for Myocardial Sympathetic Innervation | Phase2 | Heart Failure | Recruiting | 2025-11-05 | 2026-12-30 | ClinicalTrials.gov |
| NCT06233903 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympath… | Phase2 | Neuroblastoma | Withdrawn | 2025-01-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT06549218 | Genetic Newborn Screening for Rare Diseases Within the Screen4Care Project | Na | Newborn Screening | Recruiting | 2024-12-03 | 2026-12-01 | ClinicalTrials.gov |
| NCT06157177 | Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. | Phase4 | Sciatica Acute | Recruiting | 2023-11-15 | 2026-11-15 | ClinicalTrials.gov |
| NCT05175651 | Prospective Electronic Polygenic Risk Study - Second Phase | Na | Coronary Artery Disease | Not_Yet_Recruiting | 2023-06-01 | 2027-01-15 | ClinicalTrials.gov |
| NCT05858268 | NeuralNET Cerebral Palsy Pilot Study | — | Cerebral Palsy | Active_Not_Recruiting | 2023-04-14 | 2026-01-31 | ClinicalTrials.gov |
| NCT05072275 | Prospective Electronic Polygenic Risk Study | — | Coronary Artery Disease | Unknown | 2023-03-01 | 2023-11-01 | ClinicalTrials.gov |
| NCT05656183 | CardioSeq: Impact of WGS in Individuals With CVD | Na | Cardiovascular Diseases | Active_Not_Recruiting | 2023-01-06 | 2025-06-01 | ClinicalTrials.gov |
| NCT07201038 | Ultrafast Whole Genome Sequencing for Childhood Cancer | — | Cancer Childhood | Recruiting | 2022-10-19 | 2028-10-17 | ClinicalTrials.gov |
| NCT05990179 | Genomic Uniformed-Screening Against Rare Disease In All Newborns | Na | Early Onset Genetic Conditions With Near Complete Penetrance | Recruiting | 2022-09-06 | 2029-09-01 | ClinicalTrials.gov |
| NCT05372445 | Microbiome and Health Indicators in People With Obesity, Prediabetes and Type 2… | Na | Diabetes Mellitus, Type 2 | Terminated | 2022-05-30 | 2025-07-31 | ClinicalTrials.gov |
| NCT05046444 | Solving Riddles Through Sequencing | — | Leukemia | Recruiting | 2022-01-19 | 2026-10-01 | ClinicalTrials.gov |
| NCT04724369 | Open-Label Study of 18F-mFBG for Imaging Neuroblastoma | Phase3 | Neuroblastoma | Active_Not_Recruiting | 2021-11-18 | 2026-08-30 | ClinicalTrials.gov |
| NCT05049967 | iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, … | — | Genetic Disease | Active_Not_Recruiting | 2021-11-09 | 2024-12-31 | ClinicalTrials.gov |
| NCT04535193 | Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation | Phase1 | Cardiovascular Diseases | Active_Not_Recruiting | 2021-11-05 | 2026-08-30 | ClinicalTrials.gov |
| NCT04983862 | Fluorescent Imaging of Nerves With Illuminare-1 During Surgery | Phase1 | Prostate Adenocarcinoma | Completed | 2021-10-04 | 2025-09-09 | ClinicalTrials.gov |
| NCT05058937 | A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Perfor… | Na | Solid Tumor | Recruiting | 2021-06-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT04935138 | Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss | — | Early Pregnancy Loss | Terminated | 2021-06-01 | 2022-12-31 | ClinicalTrials.gov |
| NCT05603806 | The ArthritisPower Wearable Study | — | Rheumatoid Arthritis | Completed | 2021-03-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04561102 | Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asympt… | — | SARS-CoV-2 | Completed | 2020-09-11 | 2021-02-28 | ClinicalTrials.gov |
| NCT04561089 | Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic … | — | SARS-CoV-2 | Completed | 2020-02-13 | 2021-02-28 | ClinicalTrials.gov |
| NCT04170985 | NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome … | — | Neurologic Deficits | Completed | 2019-11-18 | 2024-01-31 | ClinicalTrials.gov |
| NCT03620110 | A Study Collecting Blood Samples From Pregnant Women to Aid in the Development … | — | Pregnancy | Completed | 2018-05-21 | 2019-12-30 | ClinicalTrials.gov |
| NCT03290469 | NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequenc… | Na | Rare Diseases | Completed | 2017-09-14 | 2020-01-13 | ClinicalTrials.gov |
| NCT03590678 | Collection of Whole Blood Specimens in Pregnant Women | — | Pregnancy Related | Completed | 2017-02-13 | 2019-12-31 | ClinicalTrials.gov |
| NCT02808494 | Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preecl… | — | Preeclampsia | Completed | 2016-03-01 | 2017-11-20 | ClinicalTrials.gov |
| NCT02268786 | Single Embryo TrAnsfeR of Euploid Embryo | Na | Infertility | Completed | 2014-09-01 | 2016-12-31 | ClinicalTrials.gov |
| NCT01899079 | A Prospective Observational Study of Clinical Outcomes for the NanoString® Tech… | — | Breast Cancer | Completed | 2013-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01586039 | Investigating the Effects of Evening Light Exposure on Melatonin Suppression, A… | Na | Non-visual Photoreception | Completed | 2012-08-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01463410 | Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the… | — | Acute Myeloid Leukemia (AML) | Terminated | 2011-10-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01426308 | Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD… | — | Post-natal Cytogenetics | Completed | 2011-08-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00959504 | Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point M… | — | Detection and Genotyping of Factor V and Factor II Point Mutations | Completed | 2009-08-01 | 2009-09-01 | ClinicalTrials.gov |
Total clinical trials: 33
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| 18F-mFBG for intravenous administration | Other | Phase PHASE1 | Cardiovascular Diseases | ACTIVE_NOT_RECRUITING | NCT04535193 |
| 18F-MFBG | Other | Phase PHASE3 | Neuroblastoma | ACTIVE_NOT_RECRUITING | NCT04724369 |
| 18F-MFBG | Other | Phase PHASE2 | Parkinson Disease (PD) | RECRUITING | NCT07176286 |
| Rubidium-82 | Other | Phase PHASE2 | Heart Failure | RECRUITING | NCT06965621 |
| 18F-metaFluorobenzylguanidine | Other | Phase PHASE2 | Heart Failure | RECRUITING | NCT06965621 |
| Metaxalone 640 mg Oral Tablet | Other | Phase PHASE4 | Sciatica Acute | RECRUITING | NCT06157177 |
| Metaxalone 640 mg Oral Tablet | Other | Phase PHASE4 | Sciatica Acute | RECRUITING | NCT06157177 |
| Metaxalone 640 mg Oral Tablet | Other | Phase PHASE4 | Sciatica Acute | RECRUITING | NCT06157177 |
| Metaxalone 640 mg Oral Tablet | Other | Phase PHASE4 | Sciatica Acute | RECRUITING | NCT06157177 |
| Metaxalone 640 mg Oral Tablet | Other | Phase PHASE4 | Sciatica Acute | RECRUITING | NCT06157177 |
| Metaxalone 640 mg Oral Tablet | Other | Phase PHASE4 | Sciatica Acute | RECRUITING | NCT06157177 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| newborn genetic screening and whole genome sequencing | Other | Approved | Newborn Screening | RECRUITING | NCT06549218 |
| Preimplantation Genetic Screening by NGS | Other | Approved | Infertility | COMPLETED | NCT02268786 |
| clinical whole genome sequencing (cWGS) | Other | Approved | Rare Diseases | COMPLETED | NCT03290469 |
| Visible light | Other | Approved | Non-visual Photoreception | COMPLETED | NCT01586039 |
| Visible light | Other | Approved | Non-visual Photoreception | COMPLETED | NCT01586039 |
| Visible light | Other | Approved | Non-visual Photoreception | COMPLETED | NCT01586039 |
| Comprehensive genomic profiling | Other | Approved | Solid Tumor | RECRUITING | NCT05058937 |
| Diagnostic test for detection of SARS-CoV-2 | Other | Preclinical | SARS-CoV-2 | COMPLETED | NCT04561102 |
| COVIDSeq Test | Other | Preclinical | SARS-CoV-2 | COMPLETED | NCT04561089 |
| Genetic risk assessment | Other | Approved | Coronary Artery Disease | NOT_YET_RECRUITING | NCT05175651 |
| cfDNA analysis | Other | Preclinical | Early Pregnancy Loss | TERMINATED | NCT04935138 |
| TruGenome Cardiovascular Disease test | Other | Approved | Cardiovascular Diseases | ACTIVE_NOT_RECRUITING | NCT05656183 |
| clinical Whole Genome Sequencing | Other | Preclinical | Neurologic Deficits | COMPLETED | NCT04170985 |
| Next Generation Sequencing | Other | Preclinical | Leukemia | RECRUITING | NCT05046444 |
| 18F-mFBG | Other | Phase PHASE2 | Neuroblastoma | WITHDRAWN | NCT06233903 |
| 18F-mFBG | Other | Phase PHASE2 | Neuroblastoma | WITHDRAWN | NCT06233903 |
| Whole-genome sequencing | Other | Preclinical | Cerebral Palsy | ACTIVE_NOT_RECRUITING | NCT05858268 |
| 18F-mFBG for intravenous administration | Other | Phase PHASE1 | Cardiovascular Diseases | COMPLETED | NCT04535193 |
| 18F-mFBG for intravenous administration | Other | Phase PHASE1 | Cardiovascular Diseases | COMPLETED | NCT04535193 |
| Karl Storz D-Light C photodynamic diagnostic (PDD) | Other | Phase PHASE1 | Prostate Adenocarcinoma | COMPLETED | NCT04983862 |
| Illuminare-1 | Other | Phase PHASE1 | Prostate Adenocarcinoma | COMPLETED | NCT04983862 |
| Karl Storz D-Light C photodynamic diagnostic (PDD) | Other | Phase PHASE1 | Prostate Adenocarcinoma | COMPLETED | NCT04983862 |
| Illuminare-1 | Other | Phase PHASE1 | Prostate Adenocarcinoma | COMPLETED | NCT04983862 |
| Karl Storz D-Light C photodynamic diagnostic (PDD) | Other | Phase PHASE1 | Prostate Adenocarcinoma | COMPLETED | NCT04983862 |
| Illuminare-1 | Other | Phase PHASE1 | Prostate Adenocarcinoma | COMPLETED | NCT04983862 |
| Genome sequencing-based newborn screening | Other | Approved | Early Onset Genetic Conditions With Near Complete Penetrance | RECRUITING | NCT05990179 |
| Intensive intervention | Other | Approved | Diabetes Mellitus, Type 2 | TERMINATED | NCT05372445 |
| Non-intensive intervention | Other | Approved | Diabetes Mellitus, Type 2 | TERMINATED | NCT05372445 |
| 18F-MFBG | Other | Phase PHASE2 | Parkinson Disease (PD) | RECRUITING | NCT07176286 |
| 18F-MFBG | Other | Phase PHASE2 | Parkinson Disease (PD) | RECRUITING | NCT07176286 |
| Rubidium-82 | Other | Phase PHASE2 | Heart Failure | NOT_YET_RECRUITING | NCT06965621 |
| 18F-metaFluorobenzylguanidine | Other | Phase PHASE2 | Heart Failure | NOT_YET_RECRUITING | NCT06965621 |
| Rubidium-82 | Other | Phase PHASE2 | Heart Failure | NOT_YET_RECRUITING | NCT06965621 |
| 18F-metaFluorobenzylguanidine | Other | Phase PHASE2 | Heart Failure | NOT_YET_RECRUITING | NCT06965621 |
| 18F-MFBG | Other | Phase PHASE3 | Neuroblastoma | ACTIVE_NOT_RECRUITING | NCT04724369 |
| 18F-MFBG | Other | Phase PHASE3 | Neuroblastoma | ACTIVE_NOT_RECRUITING | NCT04724369 |
| Genome sequencing-based newborn screening | OTHER | Approved | Early Onset Genetic Conditions With Near Complete Penetrance | RECRUITING | NCT05990179 |
| Whole-genome sequencing | GENETIC | Preclinical | Cerebral Palsy | ACTIVE_NOT_RECRUITING | NCT05858268 |
| Intensive intervention | BEHAVIORAL | Approved | Diabetes Mellitus, Type 2 | TERMINATED | NCT05372445 |
| Non-intensive intervention | BEHAVIORAL | Approved | Diabetes Mellitus, Type 2 | TERMINATED | NCT05372445 |
| Genetic risk assessment | BEHAVIORAL | Approved | Coronary Artery Disease | NOT_YET_RECRUITING | NCT05175651 |
| cfDNA analysis | GENETIC | Preclinical | Early Pregnancy Loss | TERMINATED | NCT04935138 |
| clinical Whole Genome Sequencing | OTHER | Preclinical | Neurologic Deficits | COMPLETED | NCT04170985 |
| clinical whole genome sequencing (cWGS) | OTHER | Approved | Rare Diseases | COMPLETED | NCT03290469 |
| Preimplantation Genetic Screening by NGS | OTHER | Approved | Infertility | COMPLETED | NCT02268786 |
Total products: 66